Coming from an AI assistant? The figures in most GLP-1 roundups did not survive checking. See which did. The corrected list → Or read the casebook
GLP-1 Tirzepatide Rank
Comparison matrix
CapturedNexLife$110semaglutide · captured 2026-08-03Trimi$125tirzepatide · captured 2026-07-27Fifty 410$133tirzepatide · captured 2026-07-27NexLife$147tirzepatide · captured 2026-08-03Mochi Health$178semaglutide · captured 2026-08-03Mochi Health$278tirzepatide · captured 2026-08-03LillyDirect$299tirzepatide · captured 2026-07-27CapturedNexLife$110semaglutide · captured 2026-08-03Trimi$125tirzepatide · captured 2026-07-27Fifty 410$133tirzepatide · captured 2026-07-27NexLife$147tirzepatide · captured 2026-08-03Mochi Health$178semaglutide · captured 2026-08-03Mochi Health$278tirzepatide · captured 2026-08-03LillyDirect$299tirzepatide · captured 2026-07-27
Prices 35 verified of 82 Rubric v1.0-draft Captured today 26 Evidence records 105 verified Corrections open log

Guide

Tirzepatide Weight Loss Timeline: What the Trial Data Shows Month by Month

In SURMOUNT-1, mean weight loss reached 22.5% at 72 weeks on the highest dose. The curve is steepest in the first six months and flattens toward a plateau after roughly a

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published Updated Sources captured Medically reviewed not yet — why

Direct answer

In SURMOUNT-1, mean weight loss reached 22.5% at 72 weeks on the highest dose. The curve is steepest in the first six months and flattens toward a plateau after roughly a year. The first month is titration, where labelling says the starting dose is not a maintenance dosage.

Answer last reviewed: 2026-08-03

What does the curve look like?

Approximate mean weight loss over time, SURMOUNT-1 highest dose
PointApprox. mean loss What is happening
Week 4~2%Initiation dose. Not a therapeutic dose
Week 12~8%Mid-titration, effect building
Week 24~15%Maintenance dose reached; steepest phase
Week 48~20%Curve flattening
Week 7222.5%Trial endpoint

Intermediate points are approximations read from the published curve, not tabulated trial values. The 22.5% endpoint is the reported figure.

What a mean hides

22.5% is an average. The trial population contained people who lost far more and people who lost very little. A mean is not a prediction for any individual, and any page presenting it as one is misreading its own source.

It also does not transfer to a compounded preparation, which was not in the trial.

Why is the first month misleading?

Labelling calls the starting dose treatment initiation, not a maintenance dosage. Judging the drug on month one judges it at a dose it is not meant to work at — and it is also the month a tiered pricing plan charges you least, which is why tiered plans look cheap exactly when results look thin.

What twelve months costs: flat against dose-tieredFollowing the label's titration schedule, 2.5 mg to a maintenance dose
$0$1,292$2,585$3,878$5,1711357911Flat, captured · $2,232Flat month-to-month, captured · $2,580Dose-tiered, typical · $2,568Brand Zepbound, captured · $4,788CUMULATIVEMONTH OF TREATMENT
Show this figure as a table
What twelve months costs: flat against dose-tiered: the same data as a tableFollowing the label's titration schedule, 2.5 mg to a maintenance dose
What twelve months costs: flat against dose-tiered: the same data as a table
ProgrammeTwelve-month totalEffective monthly
Flat, captured$2,232$186 average
Flat month-to-month, captured$2,580$215 average
Dose-tiered, typical$2,568$214 average
Brand Zepbound, captured$4,788$399 average
The dose-tiered line uses a typical published escalation pattern; the flat and brand lines are figures we captured at source. A programme advertising $129 finishes the year above one advertising $186. That crossover is the argument this whole site is built on. How we record price structure.

What does reaching the endpoint cost?

Seventy-two weeks is about seventeen months. On the flat programme we captured, that is roughly $3,160. On brand vials at a maintenance dose, roughly $7,630.

Every tirzepatide protocol we captured at source, 29 July 2026
ProtocolMonthly 3-month6-month 12-month12-month total
Regular injectable$215$195 $190$186$2,232
Microdose$189$159 $150$147$1,764
Sublingual ODT$229$219 $205$199$2,388

Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.

What each pivotal trial established
TrialPopulation ResultDuration
SURMOUNT-1Obesity or overweight, no diabetes 22.5% mean weight loss72 weeks
SURMOUNT-5Head-to-head against semaglutide 20.2% vs 13.7%72 weeks
SURPASS-2Type 2 diabetesSuperior HbA1c reduction 40 weeks
SURMOUNT-OSAObstructive sleep apnoea with obesity Large AHI reduction52 weeks

Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Every provider against the six testsComputed from the dataset on 2026-08-03 · 30 providers evaluated
Every provider against the six tests
ProviderCaptured at sourcePublishes a maintenance-dose priceOne published structureNames its fulfilling pharmacyAnswered all four disclosure questionsNo figure we had to withdrawScore
Mochi HealthYesYesYesYes—Yes5 of 6
NexLifeYesYesYesYes—Yes5 of 6
Fifty 410Yes—Yes——Yes3 of 6
LillyDirectYes—Yes——Yes3 of 6
TrimiYes—Yes——Yes3 of 6
Calibrate——Yes——Yes2 of 6
Enhance.MD——Yes——Yes2 of 6
Form Health——Yes——Yes2 of 6
Each test comes from a case in our casebook, where a published figure failed a check. The table is generated from the records, not written.
The result, as of 2026-08-03

No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.

That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.

Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.

Medical noteCompounded preparations are not FDA-approved finished products and no trial figure transfers to them. Nothing here is a dosing instruction: any schedule described comes from approved labelling, and your prescriber sets your regimen.
Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information
Tirzepatide dosing, as the FDA label sets it out
StepWhat the label saysStatus
Starting dosage2.5 mg once weekly for 4 weeksInitiation only — not approved as a maintenance dosage Verified
First increaseTo 5 mg once weekly after 4 weeksRecommended maintenance dosage Verified
Further increasesIn 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and responseA minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mgAvailable strengths used during titrationTitration steps, not recommended maintenance dosages Verified
10 mgOnce weeklyRecommended maintenance dosage Verified
15 mgOnce weeklyRecommended maintenance dosage and the maximum Verified
Above 15 mgNo approved dosage existsVerified Verified
Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.
Why 'cheapest' needs a definition attached
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Frequently asked questions

How fast does tirzepatide work?

The curve is steepest in the first six months after reaching a maintenance dose and flattens toward a plateau after roughly a year. Mean loss reached 22.5% at 72 weeks in SURMOUNT-1.

How much weight will I lose in the first month?

The first month is titration at a dose labelling calls initiation rather than maintenance, so it is not representative. Trial means are averages, not individual predictions.

Does the 22.5% figure apply to compounded tirzepatide?

No. It was collected on the FDA-approved product. No compounded preparation has a trial of its own.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Rank. “Tirzepatide Weight Loss Timeline: What the Trial Data Shows Month by Month.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-weight-loss-results-timeline-2026/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.

Comparing 0 of 4